Angea Therapeutics is advancing a gene therapy platform for the treatment of cardiovascular disorders, including ACTA2-mediated Multisystemic Smooth Muscle Dysfunction Syndrome (MSMDS) and Generalized Arterial Calcification of Infancy (GACI). The company has developed a differentiated approach that integrates vessel-specific AAV vectors with high-precision, site-specific gene editing to enhance therapeutic delivery and efficacy in vascular tissues. Angea’s lead asset has successfully completed pre-IND filing in 2025, positioning the program for advancement into clinical development.